Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

The Long Wait for a New Drug for Human African Trypanosomiasis.

Baker CH, Welburn SC.

Trends Parasitol. 2018 Oct;34(10):818-827. doi: 10.1016/j.pt.2018.08.006. Epub 2018 Sep 1. Review.

PMID:
30181071
2.

Optimization of the Promega PowerSeq™ Auto/Y system for efficient integration within a forensic DNA laboratory.

Montano EA, Bush JM, Garver AM, Larijani MM, Wiechman SM, Baker CH, Wilson MR, Guerrieri RA, Benzinger EA, Gehres DN, Dickens ML.

Forensic Sci Int Genet. 2018 Jan;32:26-32. doi: 10.1016/j.fsigen.2017.10.002. Epub 2017 Oct 5.

PMID:
29031081
3.

Sequence variation of 22 autosomal STR loci detected by next generation sequencing.

Gettings KB, Kiesler KM, Faith SA, Montano E, Baker CH, Young BA, Guerrieri RA, Vallone PM.

Forensic Sci Int Genet. 2016 Mar;21:15-21. doi: 10.1016/j.fsigen.2015.11.005. Epub 2015 Dec 1.

4.

Development and assessment of an optimized next-generation DNA sequencing approach for the mtgenome using the Illumina MiSeq.

McElhoe JA, Holland MM, Makova KD, Su MS, Paul IM, Baker CH, Faith SA, Young B.

Forensic Sci Int Genet. 2014 Nov;13:20-9. doi: 10.1016/j.fsigen.2014.05.007. Epub 2014 May 20.

5.

Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production.

Wason MS, Colon J, Das S, Seal S, Turkson J, Zhao J, Baker CH.

Nanomedicine. 2013 May;9(4):558-69. doi: 10.1016/j.nano.2012.10.010. Epub 2012 Nov 22.

6.

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD.

Mol Med. 2012 Sep 7;18:913-29. doi: 10.2119/molmed.2012.00010. Erratum in: Mol Med. 2012;18: doi/10.2119/molmed.2012.00006.erratum.

7.

Short-read, high-throughput sequencing technology for STR genotyping.

Bornman DM, Hester ME, Schuetter JM, Kasoji MD, Minard-Smith A, Barden CA, Nelson SC, Godbold GD, Baker CH, Yang B, Walther JE, Tornes IE, Yan PS, Rodriguez B, Bundschuh R, Dickens ML, Young BA, Faith SA.

Biotech Rapid Dispatches. 2012 Apr;2012:1-6.

8.

Harnessing nanoparticles to improve toxicity after head and neck radiation.

Madero-Visbal RA, Alvarado BE, Colon JF, Baker CH, Wason MS, Isley B, Seal S, Lee CM, Das S, Mañon R.

Nanomedicine. 2012 Oct;8(7):1223-31. doi: 10.1016/j.nano.2011.12.011. Epub 2012 Jan 14.

PMID:
22248817
9.

A facile nanoparticle immunoassay for cancer biomarker discovery.

Huo Q, Colon J, Cordero A, Bogdanovic J, Baker CH, Goodison S, Pensky MY.

J Nanobiotechnology. 2011 May 23;9:20. doi: 10.1186/1477-3155-9-20.

10.

Wetting and dewetting transitions on hierarchical superhydrophobic surfaces.

Boreyko JB, Baker CH, Poley CR, Chen CH.

Langmuir. 2011 Jun 21;27(12):7502-9. doi: 10.1021/la201587u. Epub 2011 May 23.

PMID:
21604679
11.

Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.

Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim M.

Gynecol Oncol. 2011 Jul;122(1):163-70. doi: 10.1016/j.ygyno.2011.03.014. Epub 2011 Apr 15.

PMID:
21496890
12.

Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats.

Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R.

Invest New Drugs. 2012 Jun;30(3):853-61. doi: 10.1007/s10637-010-9622-0. Epub 2011 Jan 4.

PMID:
21197621
13.

Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.

Basha R, Baker CH, Sankpal UT, Ahmad S, Safe S, Abbruzzese JL, Abdelrahim M.

Front Biosci (Schol Ed). 2011 Jan 1;3:797-805. Review.

PMID:
21196413
14.

Blockade of MUC1 expression by glycerol guaiacolate inhibits proliferation of human breast cancer cells.

Smith JS, Colon J, Madero-Visbal R, Isley B, Konduri SD, Baker CH.

Anticancer Agents Med Chem. 2010 Oct 1;10(8):644-6650.

PMID:
21184665
15.

Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.

Connelly SF, Isley BA, Baker CH, Gallick GE, Summy JM.

Mol Carcinog. 2010 Dec;49(12):1007-21. doi: 10.1002/mc.20684.

16.

Bioluminescence imaging correlates with tumor progression in an orthotopic mouse model of lung cancer.

Madero-Visbal RA, Colon JF, Hernandez IC, Limaye A, Smith J, Lee CM, Arlen PA, Herrera L, Baker CH.

Surg Oncol. 2012 Mar;21(1):23-9. doi: 10.1016/j.suronc.2010.07.008. Epub 2010 Aug 30.

PMID:
20801643
17.

Multicolored redox active upconverter cerium oxide nanoparticle for bio-imaging and therapeutics.

Babu S, Cho JH, Dowding JM, Heckert E, Komanski C, Das S, Colon J, Baker CH, Bass M, Self WT, Seal S.

Chem Commun (Camb). 2010 Oct 7;46(37):6915-7. doi: 10.1039/c0cc01832e. Epub 2010 Aug 4.

18.

Phosphate ester hydrolysis of biologically relevant molecules by cerium oxide nanoparticles.

Kuchma MH, Komanski CB, Colon J, Teblum A, Masunov AE, Alvarado B, Babu S, Seal S, Summy J, Baker CH.

Nanomedicine. 2010 Dec;6(6):738-44. doi: 10.1016/j.nano.2010.05.004. Epub 2010 May 27.

PMID:
20553964
19.

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD.

Neuro Oncol. 2010 Sep;12(9):917-27. doi: 10.1093/neuonc/noq044. Epub 2010 Jun 4.

20.

Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2.

Colon J, Hsieh N, Ferguson A, Kupelian P, Seal S, Jenkins DW, Baker CH.

Nanomedicine. 2010 Oct;6(5):698-705. doi: 10.1016/j.nano.2010.01.010. Epub 2010 Feb 18.

PMID:
20172051
21.

Angiogenesis: an update and potential drug approaches (review).

Abdelrahim M, Konduri S, Basha R, Philip PA, Baker CH.

Int J Oncol. 2010 Jan;36(1):5-18. Review.

PMID:
19956828
22.

Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.

Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M.

Invest New Drugs. 2011 Feb;29(1):41-51. doi: 10.1007/s10637-009-9331-8. Epub 2009 Oct 23.

PMID:
19851711
23.

Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis.

Konduri SD, Ticku J, Bobustuc GC, Sutphin RM, Colon J, Isley B, Bhakat KK, Srivenugopal KS, Baker CH.

Clin Cancer Res. 2009 Oct 1;15(19):6087-95. doi: 10.1158/1078-0432.CCR-09-0887. Epub 2009 Sep 29. Erratum in: Clin Cancer Res. 2010 Jan 1;16(1):369. Kalkunte, Srivenugopal S [corrected to Srivenugopal, Kalkunte S].

24.

A metastatic colon cancer model using nonoperative transanal rectal injection.

Donigan M, Loh BD, Norcross LS, Li S, Williamson PR, DeJesus S, Ferrara A, Gallagher JT, Baker CH.

Surg Endosc. 2010 Mar;24(3):642-7. doi: 10.1007/s00464-009-0650-9. Epub 2009 Aug 18.

PMID:
19688392
25.

Protection from radiation-induced pneumonitis using cerium oxide nanoparticles.

Colon J, Herrera L, Smith J, Patil S, Komanski C, Kupelian P, Seal S, Jenkins DW, Baker CH.

Nanomedicine. 2009 Jun;5(2):225-31. doi: 10.1016/j.nano.2008.10.003. Epub 2009 Mar 13.

PMID:
19285453
26.

Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.

Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M.

Mol Cancer Ther. 2009 Mar;8(3):533-42. doi: 10.1158/1535-7163.MCT-08-0405. Epub 2009 Mar 3.

27.

Novel murine model for colon cancer: non-operative trans-anal rectal injection.

Donigan M, Norcross LS, Aversa J, Colon J, Smith J, Madero-Visbal R, Li S, McCollum N, Ferrara A, Gallagher JT, Baker CH.

J Surg Res. 2009 Jun 15;154(2):299-303. doi: 10.1016/j.jss.2008.05.028. Epub 2008 Jun 20.

PMID:
19101690
28.

Distribution and phylogenetic relationships of Australian glow-worms Arachnocampa (Diptera, Keroplatidae).

Baker CH, Graham GC, Scott KD, Cameron SL, Yeates DK, Merritt DJ.

Mol Phylogenet Evol. 2008 Aug;48(2):506-14. doi: 10.1016/j.ympev.2008.04.037. Epub 2008 May 3.

PMID:
18583158
29.

Comparison of ultrasound-guided fine-needle aspiration biopsy with core-needle biopsy in the evaluation of thyroid nodules.

Khoo TK, Baker CH, Hallanger-Johnson J, Tom AM, Grant CS, Reading CC, Sebo TJ, Morris JC 3rd.

Endocr Pract. 2008 May-Jun;14(4):426-31.

PMID:
18558594
30.

Bcl-B expression in human epithelial and nonepithelial malignancies.

Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC.

Clin Cancer Res. 2008 May 15;14(10):3011-21. doi: 10.1158/1078-0432.CCR-07-1955.

31.

Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.

Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J, Mulligan RC, Carter BS.

J Neurosurg. 2008 May;108(5):979-88. doi: 10.3171/JNS/2008/108/5/0979.

32.

Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation.

Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL.

J Thromb Haemost. 2008 Sep;6(9):1517-24. doi: 10.1111/j.1538-7836.2008.02987.x. Epub 2008 Apr 22.

33.

Suppressibility of parathyroid hormone in primary hyperparathyroidism.

Khoo TK, Baker CH, Abu-Lebdeh HS, Wermers RA.

Endocr Pract. 2007 Nov-Dec;13(7):785-9.

PMID:
18194938
34.

Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.

Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC.

Hum Gene Ther. 2007 Oct;18(10):916-24.

PMID:
17931047
35.

Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.

Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS.

Mol Cancer Ther. 2007 Oct;6(10):2652-63. Epub 2007 Oct 3.

36.

Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells.

Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD, Yoon K, Safe S.

Cancer Res. 2007 Apr 1;67(7):3286-94.

37.

Evolution by any other name: antibiotic resistance and avoidance of the E-word.

Antonovics J, Abbate JL, Baker CH, Daley D, Hood ME, Jenkins CE, Johnson LJ, Murray JJ, Panjeti V, Rudolf VH, Sloan D, Vondrasek J.

PLoS Biol. 2007 Feb;5(2):e30. No abstract available.

39.

Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.

Abdelrahim M, Baker CH, Abbruzzese JL, Safe S.

J Natl Cancer Inst. 2006 Jun 21;98(12):855-68.

PMID:
16788159
40.

Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.

Baker CH, Trevino JG, Summy JM, Zhang F, Caron A, Nesbit M, Gallick GE, Fidler IJ.

Int J Oncol. 2006 Jul;29(1):125-38.

PMID:
16773192
41.

Molecular virology: was the 1918 flu avian in origin?

Antonovics J, Hood ME, Baker CH.

Nature. 2006 Apr 27;440(7088):E9; discussion E9-10.

PMID:
16641950
42.

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3802-12. Erratum in: Cancer Res. 2010 Jan 15;70(2):852-3.

43.

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE.

Am J Pathol. 2006 Mar;168(3):962-72.

44.
45.

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.

Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, Sundaramoorthi R, Metcalf CA 3rd, Keats JA, Sawyer TK, Gallick GE.

Mol Cancer Ther. 2005 Dec;4(12):1900-11.

46.
47.
48.

Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis.

Trevino JG, Summy JM, Gray MJ, Nilsson MB, Lesslie DP, Baker CH, Gallick GE.

Cancer Res. 2005 Aug 15;65(16):7214-22.

49.

A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.

Cengic N, Baker CH, Schütz M, Göke B, Morris JC, Spitzweg C.

J Clin Endocrinol Metab. 2005 Aug;90(8):4457-64. Epub 2005 Jun 7.

PMID:
15941870
50.

Supplemental Content

Loading ...
Support Center